Incidence and pathophysiology of hypercalcemia

Area of Science:

• Oncology
• Endocrinology
• Nephrology

Background:

• Hypercalcemia is a common complication in patients with malignant diseases, driven by various underlying mechanisms.
• The primary drivers include increased bone resorption, elevated renal tubular calcium reabsorption, and, less commonly, impaired glomerular filtration.
• Pathophysiology is heterogeneous, often categorized into humoral hypercalcemia of malignancy, localized osteolytic disease, and hematologic malignancies.

Purpose of the Study:

• To elucidate the multifaceted pathophysiology of hypercalcemia in cancer patients.
• To differentiate the distinct syndromes contributing to malignancy-associated hypercalcemia.
• To identify key mediators involved in enhanced bone resorption.

Main Methods:

• Review of existing literature on hypercalcemia in malignancy.
• Analysis of the roles of bone resorption, renal reabsorption, and gut absorption in calcium homeostasis.
• Identification of systemic and local mediators implicated in hypercalcemia.

Main Results:

• Increased bone resorption is a unifying feature across different hypercalcemia syndromes in malignancy.
• Humoral mediators, including parathyroid hormone-related protein (PTHrP), cytokines (TNF, IL-1), and vitamin D, stimulate osteoclast activity.
• Renal tubular calcium reabsorption significantly contributes to maintaining hypercalcemia in most patients.

Conclusions:

• Hypercalcemia in malignancy is a complex condition with diverse causes, necessitating tailored management strategies.
• Understanding the specific syndrome and underlying mediators is crucial for effective treatment of cancer-related hypercalcemia.
• Targeting osteoclast-mediated bone resorption and humoral factors offers therapeutic potential.